Oncology Center, Hospital Sírio-Libanês, São Paulo, Brazil.
Cancer J. 2010 May-Jun;16(3):220-5. doi: 10.1097/PPO.0b013e3181ddc7c4.
Colorectal cancer is one of the most prevalent malignancies worldwide, and its incidence continues to rise. The treatment for advanced colorectal cancer has significantly evolved in the last decade, with the addition of a number of new therapeutic agents; however, 5-fluorouracil remains at the core of most therapeutic approaches for this disease. Novel therapies targeting specific pathways have been developed for this disease, and the vascular endothelial growth factor ligand and receptor have been of particular interest. The blockade of what is considered the main angiogenic pathway is considered one of the main advances in cancer treatment. The aim of this article is to review the current status of the integration between anti-vascular endothelial growth factor therapies and cytotoxic chemotherapy, investigate what is known about development of resistance, and to explore new options of antiangiogenic treatments currently in late phases of development against colorectal cancer.
结直肠癌是全球最常见的恶性肿瘤之一，其发病率持续上升。在过去的十年中，晚期结直肠癌的治疗有了显著的发展，增加了许多新的治疗药物；然而，5-氟尿嘧啶仍然是治疗这种疾病的大多数治疗方法的核心。针对这种疾病，已经开发出了针对特定途径的新型治疗方法，血管内皮生长因子配体和受体特别受到关注。阻断被认为是主要血管生成途径的方法被认为是癌症治疗的主要进展之一。本文旨在综述抗血管内皮生长因子治疗与细胞毒性化疗相结合的现状，探讨耐药性的发展情况，并探讨目前针对结直肠癌处于后期开发阶段的新型抗血管生成治疗方案。
